Anna van Rhenen

1.7k total citations
39 papers, 1.2k citations indexed

About

Anna van Rhenen is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Anna van Rhenen has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 8 papers in Oncology and 7 papers in Genetics. Recurrent topics in Anna van Rhenen's work include Acute Myeloid Leukemia Research (19 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Anna van Rhenen is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Anna van Rhenen collaborates with scholars based in Netherlands, United States and United Kingdom. Anna van Rhenen's co-authors include Sonja Zweegman, N Feller, Gerrit Jan Schuurhuis, Gert J. Ossenkoppele, Angèle Kelder, Bijan Moshaver, Elwin Rombouts, August H. Westra, Guus A.M.S. van Dongen and Marjolein A. van der Pol and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Anna van Rhenen

34 papers receiving 1.2k citations

Peers

Countries citing papers authored by Anna van Rhenen

Since Specialization

Citations

This map shows the geographic impact of Anna van Rhenen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna van Rhenen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna van Rhenen more than expected).

Fields of papers citing papers by Anna van Rhenen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna van Rhenen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna van Rhenen. The network helps show where Anna van Rhenen may publish in the future.

Co-authorship network of co-authors of Anna van Rhenen

This figure shows the co-authorship network connecting the top 25 collaborators of Anna van Rhenen. A scholar is included among the top collaborators of Anna van Rhenen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna van Rhenen. Anna van Rhenen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane 2025 ·Cardio-Oncology ·Marijke Linschoten, (unknown), Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E.D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen A. Crommelin, (unknown), Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen	2
2	Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD 2025 ·Hematology ·(unknown), Anna van Rhenen, Renske M.T. ten Ham, Moniek A. de Witte, Jürgen Kuball	0
3	Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study 2025 ·Seminars in Arthritis and Rheumatism ·Julia Spierings, Giulia Bandini, Yannick Allanore, Nicoletta Del Papa, (unknown), Oliver Distler, Daniel E. Furst, Raffaella Greco, Dinesh Khanna, (unknown), (unknown), Mandana Nikpour, Anna van Rhenen, Jacob M. van Laar, Michael Hughes	1
4	Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT 2025 ·Bone Marrow Transplantation ·(unknown), (unknown), (unknown), Anna van Rhenen, Laura G.M. Daenen, (unknown), (unknown), (unknown), Frans M. Verduyn Lunel, (unknown), Rob Fijnheer, Henk‐Jan Prins, Kasper Westinga, Julia Drylewicz, Jürgen Kuball, Moniek A. de Witte	2
5	Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis 2025 ·Leukemia ·(unknown), Anna van Rhenen, Patrycja Gradowska, Folkert W. Asselbergs, Marijke Linschoten	0
6	PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study 2024 ·Blood ·Nicole R. Grieselhuber, (unknown), Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, (unknown), Jay Yang, Pankit Vachhani, Joseph G. Jurcic, Caspian Oliai, (unknown), (unknown), Anna van Rhenen, Marcello Rotta, (unknown), Juan Pinelli, Tara Chen, Amir T. Fathi	0
7	Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic review 2024 ·Neuro-Oncology Advances ·(unknown), (unknown), Sandra Crnko, Rick Brandsma, Anna van Rhenen, (unknown), Niels Bovenschen, Gertjan J.L. Kaspers, T.W.H. Flinsenberg	0
8	Intracardiac echocardiography‐guided biopsies for right‐sided intracardiac tumors: An optimized diagnostic algorithm and case illustrations 2024 ·Catheterization and Cardiovascular Interventions ·Arco J. Teske, (unknown), Adriaan O. Kraaijeveld, Lysette N. Broekhuizen, Dirk van Osch, Eelke Gort, Anna van Rhenen, (unknown), Michiel Voskuil	1
9	Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data 2024 ·Blood Advances ·(unknown), Mieke W.H. Roeven, (unknown), Annoek E. C. Broers, (unknown), Anna van Rhenen, (unknown), (unknown), Peter van Balen, Maria T. Kuipers, Karen M. K. de Vooght, Linde M. Morsink, Jürgen Kuball, Erfan Nur, Moniek A. de Witte	2
10	Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation 2023 ·Journal of Scleroderma and Related Disorders ·(unknown), (unknown), Rick Admiraal, Anna van Rhenen, Stefan Nierkens, Jacob M. van Laar, Julia Spierings	1
11	Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report 2021 ·Lara D. Veeken ·(unknown), Helen L. Leavis, Pieter van Paassen, Anna van Rhenen, Sjoerd A.M.E.G. Timmermans, Evelien Ton, Jacob M. van Laar, Julia Spierings	3
12	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes 2019 ·Blood Advances ·Jurgen Langenhorst, Charlotte van Kesteren, Erik M. van Maarseveen, Thomas P. C. Dorlo, Stefan Nierkens, Caroline A. Lindemans, Moniek A. de Witte, Anna van Rhenen, (unknown), Marc Bierings, Jürgen Kuball, Alwin D. R. Huitema, Jaap Jan Boelens	45
13	Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics 2019 ·JACC CardioOncology ·(unknown), Marijke Linschoten, Maarten J. Cramer, Eelke Gort, Anna van Rhenen, Folkert W. Asselbergs, Pieter A. Doevendans, Arco J. Teske	21
14	IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis 2018 ·Cell Reports ·(unknown), Noortje van Gils, (unknown), Anna van Rhenen, (unknown), Fedor Denkers, David C. de Leeuw, Marjon A. Smit, (unknown), (unknown), Renée X. de Menezes, (unknown), Margaretha G.M. Roemer, (unknown), S. Heukelom, Sonja Zweegman, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, Linda Smit	16
15	Cardio-oncology: an overview on outpatient management and future developments 2018 ·Netherlands Heart Journal ·Arco J. Teske, Marijke Linschoten, (unknown), (unknown), Tim Leiner, Elsken van der Wall, Jürgen Kuball, Anna van Rhenen, Pieter A. Doevendans, Maarten J. Cramer, Folkert W. Asselbergs	27
16	Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography 2017 ·PLoS ONE ·Marije G. Gerritsen, Martin J. Willemink, Esther Pompe, Tjomme van der Bruggen, Anna van Rhenen, Jan Willem J. Lammers, Frank J. Wessels, Ralf W. Sprengers, Pim A. de Jong, Monique C. Minnema	31
17	High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2 2011 ·Leukemia Research ·Martine E.D. Chamuleau, G.J. Ossenkoppele, Anna van Rhenen, (unknown), (unknown), Adri Zevenbergen, Gerrit‐Jan Schuurhuis, Arjan A. van de Loosdrecht	33
18	Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML 2009 ·European Journal of Cancer ·Monique Terwijn, N Feller, Anna van Rhenen, Angèle Kelder, Guus Westra, Sonja Zweegman, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis	56
19	A case of colonic mantle cell lymphoma: new insights in a rare disease 2009 ·Endoscopy ·Hendrikus J.M. Pullens, Anna van Rhenen, Rob Fijnheer, (unknown)	1
20	Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission 2007 ·Leukemia ·Anna van Rhenen, Bijan Moshaver, Angèle Kelder, N Feller, Aggie Nieuwint, Sonja Zweegman, G.J. Ossenkoppele, Gerrit‐Jan Schuurhuis	144

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact